Search Results
Your search for A matches 32881 pages
Showing 17501 - 17550Wendy S. Harpham, MD, FACP, Writes Gift Book to Change the Conversation About Hope for Cancer Survivors
Recently, Curant House announced the publication of Healing Hope: Through and Beyond Cancer by Wendy S. Harpham, MD, FACP, a physician-survivor of non-Hodgkin lymphoma and award-winning thought leader in survivorship. In this book (her eighth), Dr. Harpham presents 50 illness-related aphorisms in...
AACR 2018: Pilot Study of Neoadjuvant Nivolumab in Resectable NSCLC
In a pilot study reported at the 2018 American Association for Cancer Research (AACR) Annual Meeting (Abstract CT079) and in The New England Journal of Medicine by Forde et al, neoadjuvant nivolumab therapy was found to be feasible and active in patients with resectable non–small cell lung...
Axicabtagene Ciloleucel CAR T-Cell Therapy Active in Refractory Large B-Cell Lymphoma
As reported at the 2017 American Society of Hematology (ASH) Meeting & Exposition and in The New England Journal of Medicine by Sattva S. Neelapu, MD, of The University of Texas MD Anderson Cancer Center, and colleagues, a phase II trial has shown high activity of autologous anti-CD19 chimeric...
AACR 2018: Boosting T-Cell Memory May Result in Longer-Lasting Responses in Patients Treated With Checkpoint Blockade Immunotherapies
Some T cells have excellent memories. These subtypes—known as memory T cells—may explain why some immunotherapies are more effective than others and could potentially lead to researchers designing more effective studies using combination checkpoint blockade treatments, according to...
AACR 2018: New Liquid Biopsy–Based Cancer Model Reveals Data on Chemoresistance in SCLC
Small cell lung cancer (SCLC) accounts for 14% of all lung cancers and is often rapidly resistant to chemotherapy, resulting in poor clinical outcomes. Treatment has changed little for decades, but a study at The University of Texas MD Anderson Cancer Center offers a potential explanation for...
AACR 2018: Adjuvant Pembrolizumab in High-Risk Stage III Melanoma
As reported at the 2018 American Association for Cancer Research (AACR) Annual Meeting (Abstract CT001) and in The New England Journal of Medicine by Eggermont et al, the phase III EORTC 1325/KEYNOTE 054 trial has shown that adjuvant pembrolizumab (Keytruda) significantly prolonged recurrence-free...
FDA Approves Fostamatinib Disodium Hexahydrate for Chronic Immune Thrombocytopenia in Adult Patients
On April 17, the U.S. Food and Drug Administration (FDA) approved fostamatinib disodium hexahydrate (Tavalisse) for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. Fostamatinib is an oral spleen ...
An Inspiring Experience at Cancer Control for Primary Care Course in Bhutan
I’ll admit it. When I was first asked if I would chair the Cancer Control for Primary Care (CCPC) Course in Bhutan, I immediately exclaimed yes... and then sheepishly went to look up where exactly Bhutan was on a map. For the uninitiated, Bhutan is a country nestled between India and Tibet in the...
2018 Quality Payment Program: ASCO’s Top 10 Things to Know
The second year of the Quality Payment Program (QPP), established by the Medicare Access and CHIP Reauthorization Act (MACRA), began on January 1, 2018. This year, oncology practices face more robust quality reporting requirements to successfully participate in QPP and avoid a financial penalty in...
ASCO Launches New Website Focused on the Business of Oncology
ASCO is launching ASCO Practice Central, a new website that serves as an online information hub to help oncology professionals navigate a complicated and ever-changing practice environment while providing high-quality patient care. The first ASCO website dedicated to the business of oncology, ASCO...
Educate Patients on Safe Storage and Disposal of Pain Medications With ASCO Answers
National Prescription Drug Take Back Day is April 28, 2018. Help ASCO educate patients about how to dispose of unused or expired medications by equipping them with the ASCO Answers fact sheet on Safe Storage and Disposal of Pain Medications. Download a free copy at www.cancer.net/ascoanswers or...
ASCO Honors Leaders in Cancer Care With 2018 Special Awards
ASCO and ASCO’s Conquer Cancer Foundation are proud to recognize the winners of ASCO’s Special Awards and Conquer Cancer’s Women Who Conquer Cancer Mentorship Awards. The recipients of these awards include researchers, patient advocates, and global oncology leaders who have worked to transform...
Skin Cancer Foundation Awards Research Grants
DURING THE RECENT American Academy of Dermatology Annual Meeting in San Diego, The Skin Cancer Foundation hosted a reception to announce the winners of its annual research grant awards. The Skin Cancer Foundation’s grants program provides research funding to support dermatology department research...
Updated NCCN Guidelines® for Newly Diagnosed Glioblastoma
THE NATIONAL COMPREHENSIVE Cancer Network (NCCN) has updated its Clinical Practice Guidelines in Oncology for Central Nervous System Cancers (NCCN Guidelines®) to recommend alternating electric field therapy (also known as tumor-treating fields, Optune) in combination with temozolomide as a...
AACR Announces 2018 Class of Fellows
THE AMERICAN ASSOCIATION for Cancer Research (AACR) recently announced its newly elected class of Fellows of the AACR Academy. The mission of the AACR Academy is to recognize and honor distinguished scientists whose major scientific contributions have propelled significant innovation and progress...
A Clinician’s Guide to Treating Patients With Glioblastoma
Glioblastoma, a grade 4 astrocytoma, is the most common and most aggressive form of primary brain tumors in adults. The most recent guidance on molecular profiling, diagnostic and prognostic factors, and treatments for newly diagnosed and recurrent diseases was described in the Journal of Oncology ...
A Career Based on Service: Both Medical and Military
For this installment in the Living a Full Life series of articles, Edith Peterson Mitchell, MD, was interviewed by Guest Editor Jame Abraham, MD, FACP. Dr. Mitchell is Clinical Professor of Medicine and Medical Oncology in the Division of Medical Oncology at Thomas Jefferson University as well as ...
NIH Completes In-Depth Genomic Analysis
RESEARCHERS FUNDED by the National Institutes of Health (NIH) have completed a detailed genomic analysis, known as the Pan-Cancer Atlas, on a data set of molecular and clinical information from over 10,000 tumors representing 33 types of cancer. The Pan-Cancer Atlas, published as a collection of...
Xiang Zhang, PhD, Receives Sue Eccles Young Investigator Award
XIANG ZHANG, PhD, Associate Professor and McNair Scholar at the Lester and Sue Smith Breast Center, part of the National Cancer Institute–designated Dan L Duncan Comprehensive Cancer Center at Baylor College of Medicine, has been named the 2018 recipient of the Sue Eccles Young Investigator Award...
Fine-Tuning Treatment in Myeloma and Leukemia
It is a difficult task to include every notable presentation from the 2017 American Society of Hematology (ASH) Annual Meeting & Exposition. In addition to our more comprehensive coverage of the news from that meeting over the past several issues, below are summaries of additional key...
Expert Point of View: Marisa Weiss, MD
At a press conference where the findings by Chlebowski et al were presented, Marisa Weiss, MD, Founder and Chief Medical Officer of Breastcancer.org and Director of Radiation Oncology at Lankenau Medical Center in Philadelphia, commended this study. “We could set a goal of losing 5 pounds for our...
Modest Weight Loss Reduces Breast Cancer Risk
Evidence of the numerous health benefits of weight loss continues to mount, and the hope is that doctors and patients are listening. A large observational study presented at the 2017 San Antonio Breast Cancer Symposium showed that weight loss of more than 5% is associated with a significantly lower ...
AACR 2018: KEYNOTE-189: Addition of Pembrolizumab to Chemotherapy in Metastatic NSCLC
As reported at the American Association for Cancer Research (AACR) Meeting (Abstract CT075) in the The New England Journal of Medicine by Gandhi et al, the first interim analysis of the phase III KEYNOTE-189 trial has shown significant improvement in overall and progression-free survival with the...
Expert Point of View: C. Kent Osborne, MD
C. Kent Osborne, MD, Director of the Dan L. Duncan Cancer Center at Baylor College of Medicine, Houston, and moderator of a press conference where the EMBRACA findings were presented, shared his thoughts on the study. While a few months’ improvement in the risk of disease progression may seem...
AACR 2018: CheckMate 227: Nivolumab/Ipilimumab vs Chemotherapy in NSCLC With High Tumor Mutational Burden Analysis
As reported at the 2018 American Association for Cancer Research (AACR) Meeting (Abstract CT077) and in The New England Journal of Medicine by Hellmann et al, an analysis from the phase III CheckMate 227 trial has shown that the combination of nivolumab (Opdivo) plus ipilimumab (Yervoy)...
Talazoparib Reduces Risk of Disease Progression in BRCA-Mutated Breast Cancer
In patients with BRCA-positive advanced breast cancer, talazoparib reduced the risk of disease progression or death by 46% vs chemotherapy, according to the phase III EMBRACA trial presented at the 2017 San Antonio Breast Cancer Symposium.1 “We are very pleased that the EMBRACA trial—the largest...
Distress Screening: ‘Underestimated and Overlooked’ by Cancer Specialists
The National Comprehensive Cancer Network® (NCCN®) Distress Thermometer and Problem List for Patients have been around since 1999,1 and in 2015, the American College of Surgeons Commission on Cancer mandated routine distress screening at cancer centers.2 So how successful has the cancer community...
Scott Weir, PharmD, PhD, Recipient of 2018 Janet Davison Rowley Patient Impact Research Award
Cures Within Reach, a leading global nonprofit organization focused on drug repurposing research, announced that Scott Weir, PharmD, PhD, of The University of Kansas Cancer Center, is the recipient of the 2018 Janet Davison Rowley Patient Impact Research Award. Dr. Weir serves as Director of the...
Elaine R. Mardis, PhD, Named AACR President-Elect for 2018–2019
The members of the American Association for Cancer Research (AACR) have elected Elaine R. Mardis, PhD, as President-Elect for 2018–2019. She officially became President-Elect at the 2018 AACR Annual Meeting, held in Chicago, April 14–18, and will assume the presidency in April 2019 at the 2019...
Leslie Bernstein, PhD, Receives AACR–American Cancer Society Award for Research Excellence
Biostatistician and epidemiologist Leslie Bernstein, PhD, Professor in the Division of Biomarkers of Early Detection and Prevention, Department of Population Sciences, at City of Hope, has been selected to receive the American Association for Cancer Research’s (AACR) 27th Annual American Cancer...
American Psychosocial Oncology Society Welcomes New President, President-Elect
Teresa Deschields, PhD, is the 2018 President of the American Psychosocial Oncology Society (APOS). Dr. Deschields assumed the role of President during the Society’s annual meeting held recently in Tucson. Dr. Deschields is Clinical Associate Professor in the Department of Medicine at the...
Meeting the Challenges of Providing Long-Term Psychosocial Care for Cancer Survivors
Focusing on the first year after a cancer diagnosis is necessary, but not sufficient, for delivering care to cancer survivors, according to Deborah Mayer, PhD, RN, Director of Cancer Survivorship at the UNC Lineberger Comprehensive Cancer Center at the University of North Carolina at Chapel Hill....
Health-Related Quality-of-Life Analysis of Anti–PD-1 Therapy vs Chemotherapy in Advanced Urothelial Cancer
As reported by Vaughn et al in the Journal of Clinical Oncology, a health-related quality-of-life analysis from the phase III KEYNOTE-045 trial in previously treated advanced urothelial cancer showed that patients treated with the anti–programmed cell death protein 1 immunotherapy...
Investigational in Vitro Diagnostics in Oncology Trials: Streamlined Submission Process for Study Risk Determination
On April 16, 2018, the U.S. Food and Drug Administration (FDA) issued a draft guidance, “Investigational in Vitro Diagnostics in Oncology Trials: Streamlined Submission Process for Study Risk Determination,” to describe for sponsors of certain oncology trials an optional streamlined...
AACR 2018: Short-Acting Calcium Channel Blockers Associated With Increased Risk of Pancreatic Cancer in Postmenopausal Women
Calcium channel blockers (CCBs)—specifically the short-acting form of CCBs, which are prescribed to treat high blood pressure—were associated with an increased risk of pancreatic cancer in postmenopausal women, according to a study presented at the American Assocation for Cancer...
AACR 2018: Dual Inhibition of IDO1 and PD-L1 Safe in Patients With Advanced Solid Tumors
Treatment combining the IDO1 inhibitor epacadostat and the programmed cell death ligand 1 (PD-L1) inhibitor durvalumab (Imfinzi) was found to be safe in patients with advanced solid tumors, with safety data similar to treatment with durvalumab alone, according to data presented from the ongoing...
Efforts to Make Tobacco Cessation in Cancer Survivors Standard Practice
It is well established that smoking increases the risk for developing cancer, but when it comes to tobacco cessation in the cancer survivor population, should oncologists be stepping in, and what resources should they be using? Graham W. Warren, MD, PhD, posed these questions to the audience at the ...
AACR 2018: TLR9 Agonist CMP-001/Pembrolizumab Combination Shows Early Efficacy in Patients With Metastatic Melanoma Resistant to Anti–PD-1
A combination of CMP-001, an intratumoral Toll-like receptor 9 (TLR9) agonist, and pembrolizumab (Keytruda) was well tolerated and had clinical activity in patients with metastatic melanoma resistant to programmed cell death protein 1 (PD-1) checkpoint inhibition, according to preliminary data...
Expert Point of View: Timothy Gilligan, MD, MSc
“Knowing that exercise after surgery can help women with breast cancer quickly restore their full range of arm motion is an important step forward in their care,” said Timothy Gilligan, MD, MSc, Vice Chair for Education and Associate Professor of Medicine, Case Comprehensive Cancer...
AACR 2018: Prototype Assays Suggest Highly Specific Blood Test to Screen for Cancer Is Feasible
Initial findings from the Circulating Cell-Free Genome Atlas (CCGA) study showed that prototype sequencing assays tested in this analysis may facilitate the development of a highly specific blood test for early cancer detection, according to data presented at the American Association for Cancer...
Education Plus Exercise Improves Arm Mobility After Lymph Node Dissection in Women With Breast Cancer
In breast cancer survivors after lymph node dissection, a combined education and exercise intervention resulted in patients regaining full range of motion in both arms sooner than those who received education alone, according to follow-up from a phase III clinical trial reported by Electra D....
Expert Point of View: Christopher J. Recklitis, PhD, MPH
Christopher J. Recklitis, PhD, MPH, of Dana-Farber Cancer Institute and Harvard Medical School, called the results “instructive.” He said the study highlights the need for integrating mental health care into survivorship medical care. “We’re going to have to think about suicide prevention...
Elevated Suicide Risk Among Head and Neck Cancer Survivors Demands More Integrated Psychosocial Care
In general, the risk of suicide among cancer survivors is about 50% higher than in the general population, but this risk is especially elevated among survivors of head and neck cancer, according to research presented by Nosayaba Osazuwa-Peters, BDS, MPH, CHES, of the Department of...
Lower-Dose Radiation in HPV-Positive Head and Neck Cancers After Induction Chemotherapy
The results of a phase II clinical trial suggest that patients with head and neck cancers associated with the human papillomavirus (HPV) may receive significantly lower doses of radiation safely and effectively after response to induction chemotherapy.1 These findings from the OPTIMA study,...
Enormous Cost of Failure to Screen Heavy Smokers for Lung Nodules
In 2011 the American College of Radiology Imaging Network (ACRIN) group published its publicly funded study of three annual screening chest computed tomography (CT) scans among heavy smokers aged 55 to 74.1 The results remain the first and only screening study for any cancer demonstrating a...
Promise and Challenges of CAR T-Cell Therapy for Diffuse Large B-Cell Lymphoma: ZUMA-1 Trial Results
Advancing therapeutics and augmenting curability in diffuse large B-cell lymphoma (DLBCL) have been very challenging. Although many novel approaches have offered promise and continue to be developed, we have not yet identified a clearly superior approach to R-CHOP (rituximab [Rituxan],...
2018 Treatment Algorithm for Metastatic HER2-Positive Breast Cancer
How should clinicians position anti-HER2 agents and also incorporate endocrine therapies in the treatment of metastatic HER2-positive breast cancer? At the 2018 Miami Breast Cancer Conference, this question was explored by Sunil Verma, MD, Medical Director of the Tom Baker Cancer Center and...
FDA Approves Nivolumab/Ipilimumab Combination in Intermediate- or Poor-Risk Advanced RCC
On April 16, 2018, the U.S. Food and Drug Administration (FDA) granted approvals to nivolumab (Opdivo) and ipilimumab (Yervoy) in combination for the treatment of intermediate- or poor-risk previously untreated advanced renal cell carcinoma (RCC). CheckMate 214 The approvals were based on...
Low-Dose Abiraterone With Food vs Standard-Dose Abiraterone in Castration-Resistant Prostate Cancer
In a phase II trial reported in the Journal of Clinical Oncology, Szmulewitz et al found that low-dose abiraterone (Zytiga) given with a low-fat meal was noninferior to standard-dose abiraterone in the fasting state with regard to reduction in prostate-specific antigen (PSA) levels among patients...
Tivantinib in Second-Line Treatment of MET-High Advanced Hepatocellular Carcinoma
In the phase III METIV-HCC trial reported in The Lancet Oncology, Rimassa et al found no improvement in overall survival with the investigational MET inhibitor tivantinib vs placebo in patients with advanced hepatocellular carcinoma with high MET expression previously treated with sorafenib...
